Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sandoz Group

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz reports third-quarter and nine-month 2024 sales
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz reports second-quarter sales and half-year 2024 results
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz reports first quarter 2024 sales
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz receives FDA approval for first and only denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz announces nominations to the Board of Directors and leadership change
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Sandoz announces changes in the Board of Directors
From Sandoz Group
Via GlobeNewswire
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
From Sandoz Group
Via GlobeNewswire
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
From Sandoz Group
Via GlobeNewswire
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
From Sandoz Group
Via GlobeNewswire
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
From Sandoz Group
Via GlobeNewswire
Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
From Sandoz Group
Via GlobeNewswire
Sandoz successfully issues CHF 750 million in inaugural bonds
From Sandoz Group
Via GlobeNewswire
Sandoz reports year-to-date sales for the first nine months of 2023
From Sandoz Group
Via GlobeNewswire
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
From Sandoz Group
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.